Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
WOMEN AT CARDIAC RISK - IS HRT THE ROUTE TO MAINTAINING CARDIOVASCULAR HEALTH
Autore:
OTTESEN B; SORENSEN MB;
Indirizzi:
UNIV COPENHAGEN,HVIDOVRE HOSP,DEPT OBSTET & GYNAECOL,KETTEGAARDS ALLECOPENHAGEN DENMARK
Titolo Testata:
International journal of gynaecology and obstetrics
, volume: 59, anno: 1997, supplemento:, 1
pagine: 19 - 27
SICI:
0020-7292(1997)59:<19:WACR-I>2.0.ZU;2-3
Fonte:
ISI
Lingua:
ENG
Soggetto:
HORMONE-REPLACEMENT THERAPY; ESTROGEN-PROGESTOGEN REPLACEMENT; ENDOMETRIAL CANCER RISK; POSTMENOPAUSAL WOMEN; MYOCARDIAL-INFARCTION; VENOUS THROMBOEMBOLISM; MENOPAUSE; DISEASE; MORTALITY; STROKE;
Keywords:
CARDIOVASCULAR DISEASE; POSTMENOPAUSAL WOMEN; ESTROGEN; PROGESTOGEN; HORMONE REPLACEMENT THERAPY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
46
Recensione:
Indirizzi per estratti:
Citazione:
B. Ottesen e M.B. Sorensen, "WOMEN AT CARDIAC RISK - IS HRT THE ROUTE TO MAINTAINING CARDIOVASCULAR HEALTH", International journal of gynaecology and obstetrics, 59, 1997, pp. 19-27

Abstract

Cardiovascular disease is the leading cause of death in women of postmenopausal age. Data from observational studies suggest that the risk of coronary heart disease in postmenopausal women can be reduced by 30-50% by estrogen replacement therapy. The protective effect of estrogen is multifactorial, affecting lipids, carbohydrate metabolism, hemostasis, body-fat distribution and blood pressure. Although the unopposeduse of estrogen is associated with an increased risk of endometrial cancer, this risk can be reduced or even neutralized by the addition ofprogestogen. The protection against cardiovascular disease provided by combined estrogen/progestogen treatment has been the subject of muchdebate. However, results from epidemiological studies, intervention trials and animal experiments now suggest that the addition of progestogen does not attenuate the beneficial effects of estrogen. While secondary prevention studies are needed to evaluate the various hormone regimens, the use of combined estrogen/progestogen therapy can be supported. (C) 1997 International Federation of Gynecology and Obstetrics.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/11/20 alle ore 07:26:10